Grifols gets a minority stake in Cardio3 BioSciences

Founded by a group of scientists from the Cardiovascular Center in Aalst, Belgium on a technology developed by researchers at Mayo Clinic, Cardio3 BioSciences specialises in stem-cell based biotherapeutic R&D for the treatment of cardiovascular diseases.

Barcelona, 19 January 2009 - Grifols, a Spanish holding company specialising in the pharmaceutical-hospital industry and among the leaders in plasma derivatives, gets a minority stake in biotech company Cardio3 BioSciences.

Cardio3 BioSciences was created in 2007 by a group of scientists from the Cardiovascular Center in Aalst, Belgium, based on a technology developed by Mayo Clinic (Rochester, MN, USA), a shareholder in the company. Cardio3 BioSciences’ core business is stem-cell based therapeutic research and development for the treatment of cardiovascular diseases, particularly heart failure, via the regeneration of heart muscle.

Grifols enters into Cardio3 BioSciences by partially subscribing the capital increase. This participation enables Grifols not only to continue driving R&D, but also to tap synergies and boost some of its business lines.

In fact, Grifols could become the preferred supplier of cell collection bags (Diagnostic Division), which would be produced at the Murcia facility. In addition, the biopharmaceutical engineering arm, Grifols Engineering, could become one of the technological partners in the design and operation of the new plant Cardio3 BioSciences intends to build. Cardio3 BioSciences’ two products are in clinical trials and are currently being produced at its pilot plant in Liège (Belgium).

Lastly, talks have begun over a possible license to distribute Cardio3 BioSciences’ products in Spain and Portugal once authorisation is given. Both are markets where Grifols has a solid presence in cardiology (Hospital Division, Medical Products).
About Cardio3 BioSciences and its products

Cardio3 BioSciences is mainly involved in the research and development of biotherapeutic products created from stem cells. The research conducted to date will allow, once final approval is given, the use of adult stem cells to restore heart function in patients with congestive heart failure (CHF).

C-Cure was developed in conjunction with a molecular biology research team from Mayo Clinic.

C-Cure™ is the first biotherapeutic product made from autologous stem cells. The modified adult stem cells obtained from the bone marrow of heart disease patients are the first that have been proven effective in the reconstruction of healthy myocardium in animal models of chronic heart failure.

C-Cath™ is a catheter with a specific needle design that allows the C-Cure™ therapy to be applied directly to the patient’s heart to regenerate the damaged muscle.

About Grifols

Grifols is a Spanish holding company specialising in the pharmaceutical-hospital industry, with a presence in over 90 countries. Since May 2006, Grifols has publicly traded on the Spanish electronic trading platform (the “Continuous” Market) and since January 2008 it has been listed on the IBEX 35 index. Grifols is currently the European leader in the plasma derivatives sector and is the No. 4 manufacturer worldwide. In coming years it will strengthen its leadership position as a vertically integrated company, thanks to the investments already carried out and those scheduled to be carried out in the 2008-2012 period, which amount to 400 million Euros. With regard to raw material, Grifols has its plasma supply guaranteed, with 81 plasmapheresis center in the United States. In terms of fractionating capacity, its manufacturing capacity in Barcelona (Spain) and Los Angeles (United States) allows it to meet rising market demand. Nevertheless, the company is preparing to generate steady increases over the next 8-10 years, for which it has embarked on an ambitious investment plan.